The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Biotherapeutics Cell Line Development-Global Market Insights and Sales Trends 2025
Synopsis
The global Biotherapeutics Cell Line Development market size is expected to reach US$ 591.8 million by 2029, growing at a CAGR of 6.2% from 2023 to 2029. The market is mainly driven by the significant applications of Biotherapeutics Cell Line Development in various end use industries. The expanding demands from the In-house, Outsource, Hybrid and Do-It-Yourself (DIY), are propelling Biotherapeutics Cell Line Development market. Transfection & Selection, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Single Cell Cloning segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Biotherapeutics Cell Line Development, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Biotherapeutics Cell Line Development market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Biotherapeutics Cell Line Development market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Biotherapeutics Cell Line Development sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Biotherapeutics Cell Line Development covered in this report include Becton Dickinson & Company, Beckman Coulter, Boehringer Ingelheim Group, Catalent Inc., CMC Biologics A/S, Lonza Group Ltd., EMD Millipore, Partec (Sysmex Corporation) and ProBioGen AG, etc.
The global Biotherapeutics Cell Line Development market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Becton Dickinson & Company
Beckman Coulter
Boehringer Ingelheim Group
Catalent Inc.
CMC Biologics A/S
Lonza Group Ltd.
EMD Millipore
Partec (Sysmex Corporation)
ProBioGen AG
Selexis SA
Sigma-Aldrich Co. LLC.
Sony Biotechnology Inc.
Thermo Fisher Scientific Inc.
Global Biotherapeutics Cell Line Development market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Biotherapeutics Cell Line Development market, Segment by Type:
Transfection & Selection
Single Cell Cloning
Global Biotherapeutics Cell Line Development market, by Application
In-house
Outsource
Hybrid
Do-It-Yourself (DIY)
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Biotherapeutics Cell Line Development companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
The global Biotherapeutics Cell Line Development market size is expected to reach US$ 591.8 million by 2029, growing at a CAGR of 6.2% from 2023 to 2029. The market is mainly driven by the significant applications of Biotherapeutics Cell Line Development in various end use industries. The expanding demands from the In-house, Outsource, Hybrid and Do-It-Yourself (DIY), are propelling Biotherapeutics Cell Line Development market. Transfection & Selection, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Single Cell Cloning segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Biotherapeutics Cell Line Development, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Biotherapeutics Cell Line Development market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Biotherapeutics Cell Line Development market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Biotherapeutics Cell Line Development sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Biotherapeutics Cell Line Development covered in this report include Becton Dickinson & Company, Beckman Coulter, Boehringer Ingelheim Group, Catalent Inc., CMC Biologics A/S, Lonza Group Ltd., EMD Millipore, Partec (Sysmex Corporation) and ProBioGen AG, etc.
The global Biotherapeutics Cell Line Development market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Becton Dickinson & Company
Beckman Coulter
Boehringer Ingelheim Group
Catalent Inc.
CMC Biologics A/S
Lonza Group Ltd.
EMD Millipore
Partec (Sysmex Corporation)
ProBioGen AG
Selexis SA
Sigma-Aldrich Co. LLC.
Sony Biotechnology Inc.
Thermo Fisher Scientific Inc.
Global Biotherapeutics Cell Line Development market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Biotherapeutics Cell Line Development market, Segment by Type:
Transfection & Selection
Single Cell Cloning
Global Biotherapeutics Cell Line Development market, by Application
In-house
Outsource
Hybrid
Do-It-Yourself (DIY)
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Biotherapeutics Cell Line Development companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Biotherapeutics Cell Line Development
1.1 Biotherapeutics Cell Line Development Market Overview
1.1.1 Biotherapeutics Cell Line Development Product Scope
1.1.2 Biotherapeutics Cell Line Development Market Status and Outlook
1.2 Global Biotherapeutics Cell Line Development Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Biotherapeutics Cell Line Development Market Size by Region (2018-2029)
1.4 Global Biotherapeutics Cell Line Development Historic Market Size by Region (2018-2023)
1.5 Global Biotherapeutics Cell Line Development Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Biotherapeutics Cell Line Development Market Size (2018-2029)
1.6.1 North America Biotherapeutics Cell Line Development Market Size (2018-2029)
1.6.2 Europe Biotherapeutics Cell Line Development Market Size (2018-2029)
1.6.3 Asia-Pacific Biotherapeutics Cell Line Development Market Size (2018-2029)
1.6.4 Latin America Biotherapeutics Cell Line Development Market Size (2018-2029)
1.6.5 Middle East & Africa Biotherapeutics Cell Line Development Market Size (2018-2029)
2 Biotherapeutics Cell Line Development Market by Type
2.1 Introduction
2.1.1 Transfection & Selection
2.1.2 Single Cell Cloning
2.2 Global Biotherapeutics Cell Line Development Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Biotherapeutics Cell Line Development Historic Market Size by Type (2018-2023)
2.2.2 Global Biotherapeutics Cell Line Development Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Biotherapeutics Cell Line Development Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Biotherapeutics Cell Line Development Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Biotherapeutics Cell Line Development Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Biotherapeutics Cell Line Development Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Biotherapeutics Cell Line Development Revenue Breakdown by Type (2018-2029)
3 Biotherapeutics Cell Line Development Market Overview by Application
3.1 Introduction
3.1.1 In-house
3.1.2 Outsource
3.1.3 Hybrid
3.1.4 Do-It-Yourself (DIY)
3.2 Global Biotherapeutics Cell Line Development Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Biotherapeutics Cell Line Development Historic Market Size by Application (2018-2023)
3.2.2 Global Biotherapeutics Cell Line Development Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Biotherapeutics Cell Line Development Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Biotherapeutics Cell Line Development Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Biotherapeutics Cell Line Development Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Biotherapeutics Cell Line Development Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Biotherapeutics Cell Line Development Revenue Breakdown by Application (2018-2029)
4 Biotherapeutics Cell Line Development Competition Analysis by Players
4.1 Global Biotherapeutics Cell Line Development Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Biotherapeutics Cell Line Development as of 2022)
4.3 Date of Key Players Enter into Biotherapeutics Cell Line Development Market
4.4 Global Top Players Biotherapeutics Cell Line Development Headquarters and Area Served
4.5 Key Players Biotherapeutics Cell Line Development Product Solution and Service
4.6 Competitive Status
4.6.1 Biotherapeutics Cell Line Development Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Becton Dickinson & Company
5.1.1 Becton Dickinson & Company Profile
5.1.2 Becton Dickinson & Company Main Business
5.1.3 Becton Dickinson & Company Biotherapeutics Cell Line Development Products, Services and Solutions
5.1.4 Becton Dickinson & Company Biotherapeutics Cell Line Development Revenue (US$ Million) & (2018-2023)
5.1.5 Becton Dickinson & Company Recent Developments
5.2 Beckman Coulter
5.2.1 Beckman Coulter Profile
5.2.2 Beckman Coulter Main Business
5.2.3 Beckman Coulter Biotherapeutics Cell Line Development Products, Services and Solutions
5.2.4 Beckman Coulter Biotherapeutics Cell Line Development Revenue (US$ Million) & (2018-2023)
5.2.5 Beckman Coulter Recent Developments
5.3 Boehringer Ingelheim Group
5.3.1 Boehringer Ingelheim Group Profile
5.3.2 Boehringer Ingelheim Group Main Business
5.3.3 Boehringer Ingelheim Group Biotherapeutics Cell Line Development Products, Services and Solutions
5.3.4 Boehringer Ingelheim Group Biotherapeutics Cell Line Development Revenue (US$ Million) & (2018-2023)
5.3.5 Catalent Inc. Recent Developments
5.4 Catalent Inc.
5.4.1 Catalent Inc. Profile
5.4.2 Catalent Inc. Main Business
5.4.3 Catalent Inc. Biotherapeutics Cell Line Development Products, Services and Solutions
5.4.4 Catalent Inc. Biotherapeutics Cell Line Development Revenue (US$ Million) & (2018-2023)
5.4.5 Catalent Inc. Recent Developments
5.5 CMC Biologics A/S
5.5.1 CMC Biologics A/S Profile
5.5.2 CMC Biologics A/S Main Business
5.5.3 CMC Biologics A/S Biotherapeutics Cell Line Development Products, Services and Solutions
5.5.4 CMC Biologics A/S Biotherapeutics Cell Line Development Revenue (US$ Million) & (2018-2023)
5.5.5 CMC Biologics A/S Recent Developments
5.6 Lonza Group Ltd.
5.6.1 Lonza Group Ltd. Profile
5.6.2 Lonza Group Ltd. Main Business
5.6.3 Lonza Group Ltd. Biotherapeutics Cell Line Development Products, Services and Solutions
5.6.4 Lonza Group Ltd. Biotherapeutics Cell Line Development Revenue (US$ Million) & (2018-2023)
5.6.5 Lonza Group Ltd. Recent Developments
5.7 EMD Millipore
5.7.1 EMD Millipore Profile
5.7.2 EMD Millipore Main Business
5.7.3 EMD Millipore Biotherapeutics Cell Line Development Products, Services and Solutions
5.7.4 EMD Millipore Biotherapeutics Cell Line Development Revenue (US$ Million) & (2018-2023)
5.7.5 EMD Millipore Recent Developments
5.8 Partec (Sysmex Corporation)
5.8.1 Partec (Sysmex Corporation) Profile
5.8.2 Partec (Sysmex Corporation) Main Business
5.8.3 Partec (Sysmex Corporation) Biotherapeutics Cell Line Development Products, Services and Solutions
5.8.4 Partec (Sysmex Corporation) Biotherapeutics Cell Line Development Revenue (US$ Million) & (2018-2023)
5.8.5 Partec (Sysmex Corporation) Recent Developments
5.9 ProBioGen AG
5.9.1 ProBioGen AG Profile
5.9.2 ProBioGen AG Main Business
5.9.3 ProBioGen AG Biotherapeutics Cell Line Development Products, Services and Solutions
5.9.4 ProBioGen AG Biotherapeutics Cell Line Development Revenue (US$ Million) & (2018-2023)
5.9.5 ProBioGen AG Recent Developments
5.10 Selexis SA
5.10.1 Selexis SA Profile
5.10.2 Selexis SA Main Business
5.10.3 Selexis SA Biotherapeutics Cell Line Development Products, Services and Solutions
5.10.4 Selexis SA Biotherapeutics Cell Line Development Revenue (US$ Million) & (2018-2023)
5.10.5 Selexis SA Recent Developments
5.11 Sigma-Aldrich Co. LLC.
5.11.1 Sigma-Aldrich Co. LLC. Profile
5.11.2 Sigma-Aldrich Co. LLC. Main Business
5.11.3 Sigma-Aldrich Co. LLC. Biotherapeutics Cell Line Development Products, Services and Solutions
5.11.4 Sigma-Aldrich Co. LLC. Biotherapeutics Cell Line Development Revenue (US$ Million) & (2018-2023)
5.11.5 Sigma-Aldrich Co. LLC. Recent Developments
5.12 Sony Biotechnology Inc.
5.12.1 Sony Biotechnology Inc. Profile
5.12.2 Sony Biotechnology Inc. Main Business
5.12.3 Sony Biotechnology Inc. Biotherapeutics Cell Line Development Products, Services and Solutions
5.12.4 Sony Biotechnology Inc. Biotherapeutics Cell Line Development Revenue (US$ Million) & (2018-2023)
5.12.5 Sony Biotechnology Inc. Recent Developments
5.13 Thermo Fisher Scientific Inc.
5.13.1 Thermo Fisher Scientific Inc. Profile
5.13.2 Thermo Fisher Scientific Inc. Main Business
5.13.3 Thermo Fisher Scientific Inc. Biotherapeutics Cell Line Development Products, Services and Solutions
5.13.4 Thermo Fisher Scientific Inc. Biotherapeutics Cell Line Development Revenue (US$ Million) & (2018-2023)
5.13.5 Thermo Fisher Scientific Inc. Recent Developments
6 North America
6.1 North America Biotherapeutics Cell Line Development Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Biotherapeutics Cell Line Development Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Biotherapeutics Cell Line Development Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Biotherapeutics Cell Line Development Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Biotherapeutics Cell Line Development Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Biotherapeutics Cell Line Development Market Dynamics
11.1 Biotherapeutics Cell Line Development Industry Trends
11.2 Biotherapeutics Cell Line Development Market Drivers
11.3 Biotherapeutics Cell Line Development Market Challenges
11.4 Biotherapeutics Cell Line Development Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
